Trial
NCT03249272
Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Duke University
Collaborators
—
Condition
Hypertrophic Cardiomyopathy
Intervention
Regadenoson
Why stopped
Sponsor withdrew funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-09-16